Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project ARGOS). In addition to the FDA, our platform powers the Lupus Landmark Study, the largest clinical study for lupus in the world, the Human Epilepsy Projects and tens of other clinical studies for pharmaceutical companies, biotechs and patient groups. More than half of the top 10 Investigational sites in the US use our platform: John Hopkins, NYU, UCSF, Yale, UPenn, Washington University in St Louis, Cornell and many others also such as Mayo Clinic, Yale, Georgetown.
View Top Employees from EmbleemaWebsite | http://www.embleema.com |
Employees | 19 (8 on RocketReach) |
Founded | 2017 |
Address | 44 W. 28th St, New York, New York 10001, US |
Technologies |
JavaScript,
HTML,
PHP
+30 more
(view full list)
|
Industry | Hospitals and Health Care, Blockchain, Healthcare Technology, Electronic Medical Records, Healthcare, Clinical Research, Clinical Trials, Medicine, Technology |
Looking for a particular Embleema employee's phone or email?
Nicolas Schmidt is the Chief Product Officer and Co-Founder of Embleema.
8 people are employed at Embleema.
Embleema is based in New York, New York.